Advances in Parkinson’s Disease

A special issue of Neurology International (ISSN 2035-8377).

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 7794

Special Issue Editor


E-Mail Website
Guest Editor
Department of Neurology, Hospital Universitario de A Coruña (HUAC), Complejo Hospitalario Universitario de A Coruña (CHUAC), C/As Xubias 84, 15006 A Coruña, Spain
Interests: movement disorders; Parkinson’s disease; neurodegenerative diseases; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Parkinson’s disease (PD) is a complex progressive neurodegenerative disorder causing motor and non-motor symptoms that result in disability, loss of patient autonomy, and caregiver burden. The correct diagnosis of PD is important for prognostic and therapeutic reasons and is essential for clinical research. Although there is no specific diagnostic marker of PD at present, ongoing research aims to develop diagnostic biomarkers for use in the clinical and preclinical stages of PD. This issue aims to summarize the most recent advances in “Clinical Diagnostics, Biomarkers and Pathology in Parkinson’s Disease”.

Studies focused on identifying diagnostic markers (clinical, neuroimaging, molecular, genetic, pathological, etc.) of PD or that enable the identification or prediction of the development of PD-related complications (cognitive impairment, dementia, psychosis, impulse control disorders, freezing of gait, etc.) are considered of interest.

I hope this Special Issue is of interest to you, and I encourage you to contribute a manuscript. Many thanks in advance.

Dr. Diego Santos-García
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • clinical
  • diagnosis
  • Parkinson’s disease
  • pathology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 2420 KiB  
Article
Safety of Deep Repetitive Transcranial Magnetic Stimulation (drTMS) against Medical Refractory Symptoms in Parkinson Syndromes: First German Real-World Data with a Specific H5 Coil
by Celine Cont, Annaliis Lehto, Nathalie Stute, Anastasia Galli, Christina Schulte, Veronika Deer, Michaela Wessler and Lars Wojtecki
Neurol. Int. 2022, 14(4), 1024-1035; https://doi.org/10.3390/neurolint14040082 - 12 Dec 2022
Cited by 2 | Viewed by 2414
Abstract
So far, deep repetitive transcranial magnetic stimulation (drTMS) has shown promising results as an add-on treatment for Parkinson’s disease (PD) but not for non-idiopathic Parkinson Syndromes (PS). We aimed to investigate the safety and feasibility of drTMS application in patients with different Parkinson [...] Read more.
So far, deep repetitive transcranial magnetic stimulation (drTMS) has shown promising results as an add-on treatment for Parkinson’s disease (PD) but not for non-idiopathic Parkinson Syndromes (PS). We aimed to investigate the safety and feasibility of drTMS application in patients with different Parkinson Syndromes and medical refractory symptoms. Multifaceted real-world data (n = 21) were retrospectively analyzed regarding adverse effects as well as short-term effects of the drTMS treatment on patients’ self-rated symptom severity and motor, cognitive, and emotional functions. The drTMS treatment with H5 coil included a sequential 1 Hz primary motor cortex stimulation contralateral to the more-affected body side and a bilateral 10 Hz stimulation of the prefrontal cortex. Overall, drTMS could be safely administered to patients with different PSs and medical refractory symptoms, but large variation was apparent in the rate and severity ratings of the reported adverse event/adverse device effect. The treatment significantly decreased the subjective main symptom severity. This effect was more pronounced in older patients with PD. Furthermore, analysis showed an improvement in depression, but no effect could be established in terms of cognitive performance. drTMS can be safely administered to patients with PS and medical refractory symptoms and can decrease the subjective motor symptom severity and depression. Full article
(This article belongs to the Special Issue Advances in Parkinson’s Disease)
Show Figures

Figure 1

11 pages, 758 KiB  
Article
The Forward and Lateral Tilt Angle of the Neck and Trunk Measured by Three-Dimensional Gait and Motion Analysis as a Candidate for a Severity Index in Patients with Parkinson’s Disease
by Hirofumi Matsumoto, Makoto Shiraishi, Ariaki Higashi, Sakae Hino, Mayumi Kaburagi, Heisuke Mizukami, Futaba Maki, Junji Yamauchi, Kenichiro Tanabe, Tomoo Sato and Yoshihisa Yamano
Neurol. Int. 2022, 14(3), 727-737; https://doi.org/10.3390/neurolint14030061 - 13 Sep 2022
Cited by 1 | Viewed by 2676
Abstract
(1) Objective: To evaluate the usefulness of a three-dimensional motion-analysis system (AKIRA®) as a quantitative measure of motor symptoms in patients with Parkinson’s disease (PD). (2) Method: This study included 48 patients with PD. We measured their motion during 2 m [...] Read more.
(1) Objective: To evaluate the usefulness of a three-dimensional motion-analysis system (AKIRA®) as a quantitative measure of motor symptoms in patients with Parkinson’s disease (PD). (2) Method: This study included 48 patients with PD. We measured their motion during 2 m of walking using AKIRA®, we calculated the tilt angles of the neck and trunk, ankle height, and gait speed, then we compared these parameters with the MDS-UPDRS and the Hoehn and Yahr scale. Furthermore, we measured these AKIRA indicators before and after 1 year of observation. (3) Results: The forward tilt angle of the neck showed a strong correlation with the scores on parts II, III, and the total MDS-UPDRS, and the tilt angle of the trunk showed a moderate correlation with those measures. The lateral tilt angle of the trunk showed a moderate correlation with a freezing of the gait and a postural instability. Regarding changes over the course of 1 year (n = 34), the total scores on part III of the MDS-UPDRS and the forward tilt angle of the neck improved, while the lateral tilt angle of the trunk worsened. (4) Conclusion: Taken together, the forward and lateral tilt angles of the neck and trunk as measured by AKIRA® can be a candidate for quantitative severity index in patients with PD. Full article
(This article belongs to the Special Issue Advances in Parkinson’s Disease)
Show Figures

Figure 1

Other

Jump to: Research

5 pages, 450 KiB  
Interesting Images
Development of Parkinsonism in a Patient with Central Pontine Myelinolysis
by Annibale Antonioni, Vittorio Rispoli, Patrik Fazio, Nico Golfrè Andreasi, Vittorio Govoni and Enrico Granieri
Neurol. Int. 2022, 14(3), 673-677; https://doi.org/10.3390/neurolint14030055 - 25 Aug 2022
Viewed by 2043
Abstract
Osmotic demyelination syndrome (ODS) is caused by damage to the pons myelin sheath and nerve cells. Although the pathophysiological mechanism responsible for the damage is not yet fully understood, it is currently believed that osmotic-type changes (especially if they are massive and too [...] Read more.
Osmotic demyelination syndrome (ODS) is caused by damage to the pons myelin sheath and nerve cells. Although the pathophysiological mechanism responsible for the damage is not yet fully understood, it is currently believed that osmotic-type changes (especially if they are massive and too rapid) cause oedema that leads to compression and, subsequently, demyelination of white matter fibres. It generally manifests with acute paraparesis/tetraparesis, dysphagia, dysarthria, diplopia, and loss of consciousness, as well as hallucinations, spasms, and other neurological symptoms related to brainstem damage. In extreme cases, the locked-in syndrome may also appear. Of note, in some cases an association between osmotic demyelinating damage and the onset of movement disorders has been documented and, although the pathophysiology is still unknown, a correlation has been postulated between ODS and movement disorders. Here, we present a patient with ODS who developed parkinsonism, thus supporting the hypothesis of a correlation between these pathological events. Full article
(This article belongs to the Special Issue Advances in Parkinson’s Disease)
Show Figures

Figure 1

Back to TopTop